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ABSTRACT. Objective. The current Juvenile Idiopathic Arthritis (JIA) Core Set was developed in 1997 to identify
the outcome measures to be used in JIA clinical trials using statistical and consensus-based techniques,
but without patient involvement. The importance of patient/parent input into the research process has
increasingly been recognized over the years. An Outcome Measures in Rheumatology (OMERACT)
JIA Core Set Working Group was formed to determine whether the outcome domains of the current
core set are relevant to those involved or whether the core set domains should be revised.
Methods. Twenty-four people from the United States, Canada, Australia, and Europe, including patient
partners, formed the working group. Guided by the OMERACT Filter 2.0 process, we performed (1)
a systematic literature review of outcome domains, (2) a Web-based survey (142 patients, 343 parents),
(3) an idea-generation study (120 parents), (4) 4 online discussion boards (24 patients, 20 parents),
and (5) a Special Interest Group (SIG) activity at the OMERACT 13 (2016) meeting.
Results. A MEDLINE search of outcome domains used in studies of JIA yielded 5956 citations, of
which 729 citations underwent full-text review, and identified additional domains to those included
in the current JIA Core Set. Qualitative studies on the effect of JIA identified multiple additional
domains, including pain and participation. Twenty-one participants in the SIG achieved consensus
on the need to revise the entire JIA Core Set.
Conclusion. The results of qualitative studies and literature review support the need to expand the
JIA Core Set, considering, among other things, additional patient/parent-centered outcomes, clinical
data, and imaging data. (J Rheumatol First Release August 15 2017; doi:10.3899/jrheum.161389)
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Juvenile idiopathic arthritis (JIA) is the most common
rheumatologic disease of childhood and a cause of acquired
disability. Multiple outcome measurement sets are currently
used in studies of JIA. These include the American College
of Rheumatology (ACR) Pediatric Response criteria1, the
ACR Provisional Criteria for Defining Clinically Inactive
Disease in Select Categories of JIA2, and the Juvenile
Arthritis Disease Activity Score (JADAS)3.
    The ACR Pediatric Response criteria consider the current
JIA Core Set items as recommended for JIA clinical trials
since 1997. This core set was developed without patient/
parent contribution and applies only to oligoarticular,
polyarticular, and systemic categories of JIA, omitting enthe-
sitis-related arthritis (ERA) and juvenile psoriatic arthritis
(jPsA)4. The 6 JIA Core Set variables are the physician’s
global assessment of disease activity, parent’s/patient’s global
assessment of overall well-being, physical function, joint
count with active arthritis, joint count with restricted motion,
and acute-phase reactants. A seventh variable, fever in the
preceding week, was added posthoc for systemic JIA5. The
current JIA Core Set has been used in evaluation of medica-
tions for selected categories of JIA, and several medications
have been approved for JIA with its use6,7,8,9. Some important
features of ERA and jPsA (rash, inflammatory back pain, and
enthesitis) are not incorporated in the current core set,
limiting the applicability across populations and settings.
    The Outcome Measures in Rheumatology (OMERACT)
has long recognized the importance of patient/parent input
into the research process. While the OMERACT filter has
been applied in validation of clinical remission criteria for
JIA10 and the JADAS, several factors warrant re-examination
of the core set: lack of patient/parent input into the current
core set, advances in the field of measurement, new
patient-reported outcomes (PRO), and improved under-
standing of the pathophysiology of JIA. 
MATERIALS AND METHODS
The OMERACT JIA Core Set Working Group was formed in 2015 with 24
members representing the United States, Canada, Australia, and Italy.
Co-chairs (AC, EMM, JEM), an OMERACT fellow (MR), OMERACT
Executive Committee mentors (COB, VS), and 2 patient representatives (JH,
JEM) served leadership roles. The working group conducted monthly
teleconferences, with additional ad-hoc working group members and organ-
izations contributing to component projects discussed below.
Systematic review. The search strategy for the systematic review of the liter-
ature was developed by a health sciences information specialist with input
from pediatric rheumatologists. It included terminology to identify all
categories of JIA, was limited to citations published during and after 1992,
and used the Clinical Queries Search String. Citations were reviewed by 2
reviewers, with at least 1 pediatric rheumatologist. Decisions regarding
inclusion were made after abstract screening and full-text review, and using
prespecified, standardized criteria. Primary and secondary outcome domains
of included publications were abstracted and categorized according to
OMERACT Filter 2.0 Core Areas11.
Wide input. Multiple efforts were made to collect input from a wide group
of participants to inform the JIA Core Set revision.
Web-based survey.A survey to gather perceptions on the domains considered
important to measure in longitudinal registry studies was developed by
pediatric rheumatologists, a patient, and the staff of an advocacy organi-
zation, with feedback from parents. Survey items focused on setting PRO,
burden of illness, access to care, and goals of treatment as priorities. The
Arthritis Foundation, a US-based advocacy group, distributed the survey to
a JIA-targeted mailing list that included adults with a history of JIA and
parents of children with JIA.
Disease Impact Idea Generation. Parents of patients with JIA at a clinic in
Genoa, Italy, were provided a blank piece of paper and asked to list all
problems caused by JIA in the child’s general health and the difficulties for
the child and his/her family in everyday life due to JIA. There was no limit
on the number of items to be listed. Items were reviewed and grouped into
domains.
Online discussion board (ODB). To gain a deeper understanding of the
patient perspective than that provided by the survey or idea-generation study,
2 sets of paired ODB were conducted in the United States, 1 with parents
(split by ages of their children) and 1 with patients (split by age). Each
private 3-day ODB was facilitated by an experienced qualitative researcher
(ST). The ODB sought to elucidate the effect of JIA on physical, mental,
and social health, and the perceived differences in health between active and
inactive JIA. The ODB format enabled elicitation, description, and prioriti-
zation of a comprehensive list of potential outcome domains relevant to
patients and/or parents12. Transcripts of respondents’ typed answers were
coded into domains regarding OMERACT Core Areas and analyzed using
NVivo 1113.
      The Web-based survey study protocol was reviewed by the Cincinnati
Children’s Hospital (CCHMC) Institutional Review Board (IRB) and is
exempt from approval (study no. 2014-6575). The ODB with no collection
of identifying information was determined to be non-human subjects
research by the CCHMC IRB. The Disease Impact Idea Generation study
was approved by the Istituto Giannina Gaslini IRB/Ethics Board.
      At the OMERACT 13 meeting, a Special Interest Group (SIG) convened
to establish consensus on 3 questions: (1) Is there a need for revision of the
current JIA Core Set? (2) Should a new expanded core domain set be relevant
for assessment of all JIA categories and include uveitis? (3) Are additional
international qualitative studies required prior to a Delphi process to prior-
itize candidate core domains?
RESULTS
Systematic review. The MEDLINE search yielded 5956
citations for screening; 729 were assigned for full-text review.
Data abstraction revealed 8 outcome domains that fall within
2 The Journal of Rheumatology 2017; 44:Part 3; doi:10.3899/jrheum.161389
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the OMERACT core areas, but are not completely covered
by the current JIA Core Set (Table 1). Details will be
published separately.
Web-based survey. Parents of children with JIA (n = 343) and
142 adults with JIA completed the survey. Many outcome
domains not included in the current JIA Core Set were
identified (Table 1). Patients prioritized outcome domains
slightly differently from parents. For example, regarding
physical health, patients prioritized the ability to manage
self-care first, followed by pain control; parents prioritized
pain control first.
Disease Impact Idea Generation. The study involved 121
parents. Twenty-one domains of disease effect were identified
(Table 2), consisting of 10 domains within OMERACT Core
Areas (Table 1).
ODB participation. Parent ODB had 10 participants each, the
adolescent ODB had 11, and the young adult ODB had 13.
Multiple outcome domains not included in the current core
set were identified (Table 1). Participants characterized
inactive disease as the absence of pain, stiffness, and
swelling; increased activity/participation; ability to be more
independent; and improved mood and sleep quality. Table 3
reports themes expressed by patients in response to
questioning about health features they notice when their
disease is quiet, as well as to what factors they expect their
healthcare provider to evaluate to measure disease activity.
Results of OMERACT SIG. Twenty-one individuals attended
the JIA Core Set SIG at OMERACT, consisting of patient
research partners, pediatric rheumatologists, adult rheuma-
tologists, radiologists, researchers, regulatory officials, and
industry representatives. After presentation of data and
discussion of the key questions, all voted unanimously to
endorse the SIG’s conclusions. First, the SIG concluded that
the entire core set should be considered for revision; rather
than focusing only on addition of PRO, the SIG suggested
consideration of imaging and other clinical data. Attendees
suggested that the systematic review include publications
prior to 1992 and that it search multiple databases. Second,
the SIG concluded that the JIA Core Set should identify all
JIA categories4. Attendees discussed the unique autoinflam-
matory features of systemic JIA, but reached consensus to
include systemic JIA at this stage. The SIG also decided to
3Morgan, et al: JIA core set revision
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Table 1. Summary of domains identified by literature review and participant input.  
Domains Organized by OMERACT                           
Core Areas
Death
     Disease                                                                                                                                                                                                                          
     Intervention                                                                                                                                                                                                            
Life effect
     ICF domains: activity and participation                                                                                                                                                      
     Quality of life                                                                                                                                                                                              
     Patient perception of health                                                                                                                                                                         
     Loss of ability to work                                                                                                                                                                                          
     Psychosocial impact                                                                                                                                                                                    
     Secondary impact on family/caregivers                                                                                                                                                                     
     Utility                                                                                                                                                                                                                               
Resource use/economic effect
     Societal                                                                                                                                                                                                                             
     Individual                                                                                                                                                                                                                   
     Healthcare                                                                                                                                                                                                                  
     Direct/indirect (productivity)                                                                                                                                                                                      
     Intangible costs                                                                                                                                                                                                                
Pathophysiological manifestations
     ICF: body function and structure                                                                                                                                                                 
     Organ function                                                                                                                                                                                                               
     Reversible manifestations                                                                                                                                                                                          
     Irreversible manifestations                                                                                                                                                                                      
     Biomarkers                                                                                                                                                                                                                    
     Surrogate outcomes                                                                                                                                                                                                          
* Systematic literature review of juvenile idiopathic arthritis studies found domains/subdomains measured to include joint count, physician’s global assessment,
functional ability, inflammatory markers, patient’s/caregiver’s global assessment, biomarkers, health-related quality of life, adverse effects, adjustment/
psychosocial health, flare, damage, fatigue, participation, ability to stop/decrease medications, growth/maturation, mental health, and bone health. Pts: patients;
ODB: online discussion boards; ICF: International Classification of Functioning, Disability and Health.
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include uveitis-related outcomes as a domain and to use the
work of an international uveitis working group to identify the
items to include14. Finally, the SIG agreed that additional
qualitative input should be gathered in other countries, with
an effort to include patients younger than 15 years, and to
inform a Delphi process to prioritize domains.
DISCUSSION
An international collaboration between multiple participant
has begun using the OMERACT process to develop an
updated Core Domain Set for assessment of JIA in clinical
trials. The preliminary data from working group projects and
unanimous voting of the OMERACT SIG support the need
to revise the current JIA Core Set. This working group has
emphasized identification of patient/parent-valued domains
because of the paucity of involvement in past JIA Core Set
development and the absence of domains, such as pain,
fatigue, and participation. The most informative of the quali-
tative approaches, the ODB, will be replicated outside the
United States for cross-cultural validation of findings.
    As a result of the JIA Core Set OMERACT SIG, the
working group will expand to include additional international
participants. We will move forward a research agenda that
addresses the knowledge gaps and priorities for revising the
current Core Set within the OMERACT framework by
expanding the systematic review, developing a conceptual
model of patient/parent experience of JIA, and conducting a
Delphi process to prioritize domains.
    Unique challenges include eliciting input from young
patients, reconciling perspectives between patients and
parent-proxy respondents, and establishing content relevance
across heterogeneous JIA subtypes in a single core set. The
immediate goal is to advance this research agenda and return
in 2018 as an OMERACT Workshop with a proposed draft
JIA Core Domain Set. Ultimately, specific instruments for
identified domains will be reviewed and/or developed to
ensure that the new core set measures are able to discriminate
between placebo and efficacious treatments in clinical trials.
ACKNOWLEDGMENT
We acknowledge the Juvenile Idiopathic Arthritis Core Set Working Group
members for their contributions to the work reported herein, in addition to
authors listed: B. Feldman, K.J. Corbin, B. Gottlieb, P. Weiss, R. James. W.
Townsend, a Health Sciences Informationalist at the University of Michigan,
contributed to the systematic literature review. We acknowledge contribu-
tions to the survey development of J. Wyatt, and PARTNERS steering
committee members and parents for feedback. S. Thornhill designed the
ODB research and facilitated the groups; L. Marrow and A. Vinci contributed
from the Arthritis Foundation; and A. Fortna and S. Luca provided research
assistance. We appreciate the thoughtful attention and discussion of the
OMERACT 13 SIG attendees, none of whom was part of the original Work
Group, and several who will join the project moving forward. 
REFERENCES
   1.    Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini
A. Preliminary definition of improvement in juvenile arthritis.
Arthritis Rheum 1997;40:1202-9.
   2.    Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N; Childhood
Arthritis Rheumatology Research Alliance; Pediatric Rheumatology
Collaborative Study Group; Paediatric Rheumatology International
Trials Organisation. American College of Rheumatology provisional
criteria for defining clinical inactive disease in select categories of
juvenile idiopathic arthritis. Arthritis Care Res 2011;63:929-36.
   3.    Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S,
Filocamo G, et al; Paediatric Rheumatology International Trials
Organisation. Development and validation of a composite disease
activity score for juvenile idiopathic arthritis. Arthritis Rheum
2009;61:658-66.
   4.    Petty RE, Southwood TR, Manners P, Baum J, Glass DN,
Goldenberg J, et al; International League of Associations for
4 The Journal of Rheumatology 2017; 44:Part 3; doi:10.3899/jrheum.161389
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2017. All rights reserved.
Table 2. Twenty-one domains of JIA disease effect identified from the Italian
Idea Generation Study.
Fatigue
Pain
Sleep disturbance
Reduction of functional ability
Restriction in autonomy and independence
Limited relations with peers
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